2023
The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Batool S, Yekula A, Khanna P, Hsia T, Gamblin A, Ekanayake E, Escobedo A, You D, Castro C, Im H, Kilic T, Garlin M, Skog J, Dinulescu D, Dudley J, Agrawal N, Cheng J, Abtin F, Aberle D, Chia D, Elashoff D, Grognan T, Krysan K, Oh S, Strom C, Tu M, Wei F, Xian R, Skates S, Zhang D, Trinh T, Watson M, Aft R, Rawal S, Agarwal A, Kesmodel S, Yang C, Shen C, Hochberg F, Wong D, Patel A, Papadopoulos N, Bettegowda C, Cote R, Srivastava S, Lee H, Carter B, Balaj L. The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Reports Medicine 2023, 4: 101198. PMID: 37716353, PMCID: PMC10591039, DOI: 10.1016/j.xcrm.2023.101198.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBiomarkersCell-Free Nucleic AcidsExtracellular VesiclesHumansLiquid BiopsyNeoplastic Cells, CirculatingConceptsLiquid biopsy
2022
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, Patel AA, Zhang DY. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering 2022, 6: 232-245. PMID: 35102279, PMCID: PMC9336539, DOI: 10.1038/s41551-021-00837-3.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCell-Free Nucleic AcidsHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyNeoplasms